EP1737864A1 - Antagonistes du cgrp selectionnes, leurs procedes de production et leur utilisation comme medicament - Google Patents

Antagonistes du cgrp selectionnes, leurs procedes de production et leur utilisation comme medicament

Info

Publication number
EP1737864A1
EP1737864A1 EP05731903A EP05731903A EP1737864A1 EP 1737864 A1 EP1737864 A1 EP 1737864A1 EP 05731903 A EP05731903 A EP 05731903A EP 05731903 A EP05731903 A EP 05731903A EP 1737864 A1 EP1737864 A1 EP 1737864A1
Authority
EP
European Patent Office
Prior art keywords
general formula
piperidine
carboxylic acid
dihydro
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP05731903A
Other languages
German (de)
English (en)
Inventor
Stephan Georg Mueller
Klaus Rudolf
Philipp Lustenberger
Dirk Stenkamp
Kirsten Arndt
Henri Doods
Gerhard Schaenzle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim International GmbH
Publication of EP1737864A1 publication Critical patent/EP1737864A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to the CGRP antagonists of the general formula
  • A is a residue of the formula
  • the compounds of the general formula (I) are prepared by methods known in principle. The following processes have proven particularly useful for the preparation of the compounds of the general formula (I) according to the invention:
  • R 1 is defined as mentioned at the beginning, ..
  • G denotes a nucleofugic group, which may be the same or different, preferably the chlorine atom, the p-nitrophenoxy or trichloromethoxy group, and
  • R 2 and R 3 are defined as mentioned at the outset, with the proviso that R 2 and R 3 contain no further free, unprotected, primary or secondary aliphatic amino function.
  • the basically two-stage reactions are generally carried out as a one-pot process, and preferably in such a way that in the first stage one of the two components (II) or (IV) with equimolar amounts of the carbonic acid derivative of the general formula (III) in one suitable solvent to react at a lower temperature, then at least equimolar amounts of other component (II) or (IV) and the reaction is terminated at a higher temperature.
  • the reactions with bis (trichloromethyl) carbonate are preferably carried out in the presence of at least 2 equivalents (based on bis (trichloromethyl) carbonate) of a tertiary base, for example triethylamine,, / -ethyldiisopropylamine, pyridine, 1, 5-diaza- bicyclo- [4.3.0] -non-5-ene, 1,4-diazabicyclo- [2.2.2] octane or 1,8-diazabicyclo- [5.4.0] -un-dec-7-ene.
  • a tertiary base for example triethylamine,, / -ethyldiisopropylamine, pyridine, 1, 5-diaza- bicyclo- [4.3.0] -non-5-ene, 1,4-diazabicyclo- [2.2.2] octane or 1,8-diazabicyclo- [5.4.0] -
  • Suitable solvents which should be anhydrous are, for example, tetrahydrofuran, dioxane, dimethylformamide, dimethylacetamide, / V-methyl-2-pyrrolidone, 1,3-dimethyl-2-imidazolidinone or acetonitrile when using bis- (trichloromethyl) - Carbonate as the carbonyl component is preferred anhydrous chlorinated hydrocarbons, for example dichloromethane, 1, 2-dichloroethane or trichlorethylene.
  • the reaction temperatures for the first reaction stage are between -30 ° C and + 25 ° C, preferably -5 ° C and + 10 ° C, for the second reaction stage between + 15 ° C and the boiling point of the solvent used, preferably between + 20 ° C and + 70 ° C
  • a and R 1 are as defined at the outset, with an amine of the general formula HNR 2 R 3 , in which R 2 and R 3 are as defined at the outset, with the proviso that they are not free further unprotected primary or secondary aliphatic Amino function included.
  • Any primary or secondary amino function additionally present in the -NR 2 R 3 radical is provided with a suitable protective group.
  • the coupling is preferably carried out using methods known from peptide chemistry (see, for example, Houben-Weyl, Methods of Organic Chemistry, Vol. 15/2), for example carbodiimides, such as, for example, dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC) or ethyl (3-dimethyaminopropyl) carbodiimide, 0- (1H-benzotriazol-1-yl) - ⁇ / > / V- / V, / V , -tetramethyIuronium hexafluorophosphate (HBTU) or tetrafluoroborate (TBTU) or 1H-benzotriazoI-1-yl-oxy-tris- (dimethylamino) -phosphonium hexafluorophosphate (BOP) can be used.
  • DEC dicyclohexylcarbodiimide
  • DI diisoprop
  • the reaction rate can be increased by adding 1-hydroxybenzotriazole (HOBt) or 3-hydroxy-4-oxo-3,4-dihydro-1, 2,3-benzotriazine (HOOBt).
  • the couplings are normally made with equimolar proportions of the coupling components and the coupling reagent in solvents such as dicblormethane, tetrahydrofuran, acetonitrile, dimethylformamide (DM), dimethyl acetamide (DMA), ⁇ / methylpyrrolidone (NMP) or mixtures of these and at temperatures between -30 and + 30 ° C, preferably -20 and + 25 ° C, carried out.
  • DIEA / -ethyldiisopropylamine
  • the mixed anhydride is obtained from the carboxylic acid of general formula (V) to be coupled and the carbonic acid monoisobutyl ester.
  • the preparation of this mixed anhydride and the coupling with the amines of the general formula HNR 2 R 3 takes place in a one-pot process, using the abovementioned solvents and at temperatures between -20 ° C. and + 25 ° C., * preferably between 0 ° C. and + 25 ° C.
  • a and R 1 are defined as mentioned at the outset and Nu is a leaving group, for example a halogen atom, such as the chlorine, bromine or iodine atom, an alkylsulfonyloxy group having 1 to 10 carbon atoms in the alkyl part, one optionally by chlorine or bromine atoms, phenylsulfonyloxy or naphthylsulfonyloxy group mono-, di- or tri-substituted by methyl or nitro groups, where the substituents can be the same or different, one 1H-imidazol-1-yl, one given 1H-pyrazol-1-yl-, 1H-1, 2,4-triazol-1-yl-, 1H-1, 2,3-triazol-1-yl-, substituted by one or two methyl groups in the carbon skeleton, 1 H-1, 2,3,4-tetrazol-1-yl, vinyl, propargyl, p-nitrophenyl, 2,4-
  • the reaction is carried out under Schotten-Baumann or Einhorn conditions, that is, the components are in the presence of at least one equivalent of an auxiliary base at temperatures between -50 ° C and + 120 ° C, preferably -10 ° C and + 30 ° C, and optionally reacted in the presence of solvents.
  • Alkali and alkaline earth metal hydroxides for example sodium hydroxide, potassium hydroxide or barium hydroxide, alkali metal carbonates, e.g. Sodium carbonate, potassium carbonate or cesium carbonate, alkali acetate, e.g.
  • Sodium or potassium acetate, and also tertiary amines for example pyridine, 2,4,6-trimethylpyridine, quinoline, triethylamine, ⁇ / -ethyldiisopropylamine, / V-ethyldicyclohexylamine, 1,4-di-azabicyclo [2.2.2] octane or 1, 8-diaza-bicyclo [5.4.0] - undec-7-ene, as solvent, for example dichloromethane, tetrahydrofuran, 1, 4-dioxane, acetonitrile, dimethylformamide, dimethylacetamide, / V-methylpyrrolidone or mixtures thereof; If alkali or alkaline earth hydroxides, alkali carbonates or acetates are used as auxiliary bases, water can also be added to the reaction mixture as cosolvent.
  • tertiary amines for example pyridine, 2,4,6-trimethylpyridine
  • novel compounds of the general formula (I) according to the invention contain one or more centers of chirality. If, for example, there are two centers of chirality, the compounds can appear in the form of two diastereomeric pairs of antipodes.
  • the invention includes the individual isomers as well as their mixtures. The respective diastereomers can be separated on the basis of their different physicochemical properties, for example by fractional crystallization from suitable solvents, by high-pressure liquid or column chromatography using chiral or preferably achiral stationary phases.
  • Racemates falling under the general formula (I) can be separated, for example, by HPLC on suitable chiral stationary phases (for example Chiral AGP, Chiralpak AD). Racemates that contain a Bavarian function can also be separated via the diastereomeric, optically active salts which, when reacted with an optically active acid, for example (+) - or (-) - tartaric acid, (+) - or (-) - Diacetyl tartaric acid, (+) - or (-) - monomethyl tartrate or (+) - camphorsulfonic acid are formed.
  • an optically active acid for example (+) - or (-) - tartaric acid, (+) - or (-) - Diacetyl tartaric acid, (+) - or (-) - monomethyl tartrate or (+) - camphorsulfonic acid are formed.
  • the racemate of a compound of the general formula (I) is reacted with one of the optically active acids given above in an equimolar amount in a solvent and the crystalline, diastereomeric, optically active salts obtained are separated using their different solubilities.
  • This implementation can be done in any kind of
  • Solvents are carried out as long as they have a sufficient difference in the solubility of the salts.
  • methanol preferably methanol,
  • Base such as sodium carbonate or potassium carbonate, or with a suitable acid, for example with dilute hydrochloric acid or aqueous methanesulfonic acid, carefully neutralized and thereby obtain the corresponding free compound in the (+) or (-) form.
  • the starting compounds of the general formula (II) are obtained if they are not are known from the literature, in accordance with the methods specified in international patent application WO 03/104236.
  • the starting compounds of the general formula (III) are commercially available.
  • Compounds of the general formula (IV) can be prepared from hydroxycarboxylic acids and amines of the general formula HNR 2 R 3 by methods familiar to the peptide chemist.
  • the compounds of the general formula (VII) can be obtained by diazotizing compounds of the general formula (VIII) with a suitable diazotizing reagent, preferably sodium nitrite in an acidic medium. If enantiomerically pure compounds are used, the corresponding enantiomerically pure hydroxycarboxylic acid compounds are obtained, the reaction taking place with retention of the configuration.
  • radicals A are defined as mentioned at the outset and X denotes a chlorine, bromine or iodine atom, analogously to methods known from the literature (Michael T. Crimmins, Kyle A. Emmitte and Jason D. Katz, Org. Lett. 2, 2165 -2167 [2000]).
  • the resulting diastereomeric products can then be separated using physico-chemical methods, preferably using chromatographic methods.
  • the hydrolytic cleavage of the chiral auxiliary, coupling with amines four general formula HNR 2 R 3 and cleavage of the benzyl protecting group also opens access to enantiomerically pure hydroxycarboxylic acid compounds of the general formula (IV).
  • the compounds of general formula (I) obtained can be converted into their physiologically tolerable salts with inorganic or organic acids, in particular for pharmaceutical applications.
  • suitable acids for this are hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, mandelic acid, malic acid, citric acid, tartaric acid or maleic acid.
  • the present invention relates to racemates if the compounds of the general formula (I) have only one chiral element.
  • the application also includes the individual diastereomeric pairs of antipodes or their mixtures, which are present when more than one chiral element is present in the compounds of the general formula (I), and the individual optically active enantiomers from which the racemates mentioned are composed.
  • Also included in the subject matter of this invention are the compounds according to the invention, including their salts, in which one or more hydrogen atoms have been replaced by deuterium.
  • the new compounds of the general formula (I) and their physiologically tolerable salts have valuable pharmacological properties which are based on their selective CGRP-antagonistic properties.
  • the invention further relates to medicaments containing these compounds, their use and their preparation.
  • the above-mentioned new compounds and their physiologically tolerable salts have CGRP antagonistic properties and show good affinities in CGRP receptor binding studies.
  • the compounds have CGRP-antagonistic properties in the pharmacological test systems described below.
  • SK-N-MC cells are cultivated in "Dulbecco's modified Eagle Medium”. The medium of confluent cultures is removed. The cells are washed twice with PBS buffer (Gibco 041-04190 M), detached by adding PBS buffer, mixed with 0.02% EDTA, and isolated by centrifugation. After resuspension in 20 ml "Balanced Salts Solution” [BSS (in mM): NaCI 120, KCI 5.4, NaHCO 3 16.2, MgS0 4 0.8, NaHPO 4 1.0, CaCI 2 1.8, D-Glucose 5.5, HEPES 30, pH 7.40] the cells are centrifuged twice at 100 xg and resuspended in BSS.
  • BSS "Balanced Salts Solution”
  • the cells are homogenized using an Ultra-Turrax and centrifuged for 10 minutes at 3000 xg. The supernatant is discarded and the pellet is recentrifuged and resuspended in Tris buffer (10 mM Tris, 50 mM NaCl, 5 mM MgCl 2 , 1 mM EDTA, pH 7.40), enriched with 1% bovine serum AiBümin and 0.1% bacitracin (1 ml / 1,000,000 cells). The homogenate is frozen at -80 ° C. Under these conditions, the membrane preparations are stable for more than 6 weeks.
  • the homogenate is diluted 1:10 with assay buffer (50 mM Tris, 150 mM NaCl, 5 mM MgCl 2 , 1 mM EDTA, pH 7.40) and homogenized for 30 seconds with an Ultra-Turrax. 230 ul of the homogenate are for 180 minutes at room temperature with 50 pM 125 l-iodotyrosyl-calcitonin gene-related peptides (Amersham) and increasing concentrations of the test substances in a total volume of 250 ⁇ l.
  • the incubation is ended by rapid filtration through GF / B glass fiber filters treated with polyethyleneimine (0.1%) using a cell harvester.
  • the radioactivity bound to protein is determined using a gamma counter. The bound radioactivity is defined as non-specific binding after the presence of 1 ⁇ M human CGRP-alpha during the incubation.
  • concentration-binding curves are analyzed with the aid of a computer-aided non-linear curve fitting.
  • SK-N-MC cells (1 million cells) are washed twice with 250 ⁇ l incubation buffer (Hanks ' HEPES, 1 mM 3-isobutyl-1-methylxanthine, 1% BSA, pH 7.4) and at 37 ° C. for 15 minutes pre-incubated. After adding CGRP (10 ⁇ l) as an agonist in increasing concentrations (10 ⁇ 11 to 10 ⁇ 6 M) or additionally of substance in 3 to 4 different concentrations, incubation is continued for 15 minutes.
  • incubation buffer Hanks ' HEPES, 1 mM 3-isobutyl-1-methylxanthine, 1% BSA, pH 7.4
  • Intracellular cAMP is then extracted by adding 20 ⁇ l of 1M HCl and centrifugation (2000 ⁇ g, 4 ° C. for 15 minutes). The supernatants are frozen in liquid nitrogen and stored at -20 ° C.
  • the cAMP contents of the samples are determined by means of a radioimmunoassay (from Amersham) and the pA 2 values of substances having an antagonistic effect are determined graphically.
  • the compounds according to the invention show CGRP-antagonistic properties in a dose range between 10 _12 to 10- 5 M. Because of their pharmacological properties, the compounds according to the invention and their salts with physiologically compatible acids are therefore suitable for the acute and prophylactic treatment of headaches, in particular migraine or cluster headaches. Furthermore, the compounds according to the invention also have a positive influence on the following diseases: non-insulin-dependent diabetes mellitus ("NIDDM”), complex regional pain syndrome (CRPS1), cardiovascular diseases, morphine tolerance, clostritium-toxin-related diarrhea, skin diseases, in particular thermal see and radiation-related skin damage including sunburn, inflammatory diseases, e.g.
  • NIDDM non-insulin-dependent diabetes mellitus
  • CRPS1 complex regional pain syndrome
  • cardiovascular diseases e.g., morphine tolerance, clostritium-toxin-related diarrhea, skin diseases, in particular thermal see and radiation-related skin damage including sunburn, inflammatory diseases, e.g.
  • the compounds according to the invention generally have an alleviating effect on painful conditions.
  • the symptoms of menopausal hot flashes caused by vasodilation and increased blood flow in estrogen-deficient women and hormone-treated prostate carcinoma patients are influenced by the CGRP antagonists of the present application in a preventive and acutely therapeutic manner, whereby this therapeutic approach before hormone substitution is characterized by a lack of side effects.
  • the dosage required to achieve a corresponding effect is expediently 0.01 to 3 mg / kg body weight with intravenous or subcutaneous administration, preferably 0.01 to 1 mg / kg body weight, with oral administration 0.01 to 20 mg / kg body weight, preferably 0.1 to 10 mg / kg Body weight, and with nasal or inhalation administration 0.01 to 10 mg / kg body weight, preferably 0.1 to 10 mg / kg body weight, each 1 to 3 times a day.
  • the compounds produced according to the invention can be carried out either alone or, if appropriate, in combination with other active substances for the treatment of migraines intravenously, subcutaneously, intramuscularly, intrarectally, intranasally, by inhalation, transdermally or orally, aerosol formulations in particular being suitable for inhalation.
  • the combinations can be administered either simultaneously or sequentially.
  • Possible drug classes as combination partners are, for example, angiotensin-II receptor antagonists, ⁇ -agonists and ⁇ -antagonists, 5-HT-i B / i D- agonists, AMPA antagonists, weak analgesics, antidepressants, antiemetics, anticonvulsants, antimuscarinics, ß-blockers, Calcium antagonists, corticosteroids, ergot alkaloids, histamine H1 receptor antagonists, neurokinin antagonists, neuroleptics, non-steroidal anti-inflammatory drugs, NO synthase inhibitors, prokinetics, selective serotonin reuptake inhibitors or other anti-migraine agents that together with one or more together usual carriers and / or diluents, for example with corn starch, milk sugar, cane sugar, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water / ethanol, water / glycerol, water /
  • the non-steroidal antiinflammatory agents aceclofenac, acemetacin, acetylsalicylic acid, azathioprine, diclofenac, diflunisal, fenbufen, fe ⁇ oprofen, flurbiprofen, ibuprofen, indometacin, lefornoxenamic acid, Phenylbutazone, piroxicam, sulfasalazine, tenoxicam, zomepirac or their physiologically tolerable salts as well as meloxicam and other selective COX2 inhibitors, such as rofecoxib and celecoxib, into consideration.
  • 5-HT-i B / i D agonists such as almotriptan, avitriptan, donitriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan as well as their physiologically acceptable salts are used.
  • the dose for these active substances is expediently 1/5 of the usually recommended lowest dose up to 1/1 of the normally recommended dose, for example 20 to 100 mg sumatriptan.
  • the invention furthermore relates to the use of the compounds according to the invention as valuable auxiliaries for the production and purification (affinity chromatography) of antibodies and, after suitable radioactive labeling, for example by tritiation of suitable precursors, for example by catalytic hydrogenation with trithium or replacement of halogen atoms by tritium, in RIA and ELISA assays and as diagnostic and analytical tools in neurotransmitter research.
  • IR, 1 H-NMR and / or mass spectra are generally available for the compounds produced. Unless stated otherwise, R f values are determined using ready-made silica gel 60 F254 TLC plates (E. Merck, Darmstadt, Article No. 1.05714) without chamber saturation.
  • the ratios given for the flow agents relate to volume units of the respective solvents.
  • the volume units given for NH 3 relate to a concentrated solution of NH 3 in water.
  • the acid, base and salt solutions used in the work-up of the reaction solutions are aqueous systems of the stated
  • Example (1c) Analogously to Example (1c) was obtained from 100 mg (0:19 mmol) of 1 ', 2'-Dihydro-2'-oxospiro-4 / - - 3, 1-chinazolin'-4,4'-piperidine-1-carboxylic acid ( R) -2- (4-amino-3-chloro-5-trifluoromethylphenyl) -1-carboxy-ethyl ester and 40 mg (0.22 mmol) of 1-methyl- [4,4 '] bipiperidinyl the product are obtained.
  • 1 capsule for powder inhalation contains: Active ingredient 1.0 mg
  • the active ingredient is ground to the grain size required for inhalants.
  • the ground active ingredient is mixed homogeneously with the milk sugar. The mixture is filled into hard gelatin capsules.
  • Composition: 1 hub contains:
  • Active ingredient 1.0 mg benzalkonium chloride 0.002 mg
  • the active ingredient and benzalkonium chloride are dissolved in water and filled into Respimat® cartridges.
  • 1 vial contains:
  • Active ingredient sodium chloride and benzalkonium chloride are dissolved in water.
  • 1 hub includes:
  • the micronized active ingredient is homogeneously suspended in the mixture of lecithin and propellant.
  • the suspension is filled into a pressure vessel with a metering valve.
  • Example VI The active ingredient and excipients are dissolved in water and filled into a suitable container.
  • Polysorbate 80 sodium chloride, monopotassium dihydrogen phosphate and disodium hydro- Dissolve gene phosphate in water for injections (Wfl); Add human serum albumin; Dissolve the active ingredient while heating; fill up to batch volume with Wfl; fill in ampoules.
  • composition active substance 10 mg
  • Preparation Dissolve mannitol in water for injections (Wfl); Add human serum albumin; Dissolve the active ingredient while heating; fill up to batch volume with Wfl; fill in vials; freeze-dry.
  • Preparation Dissolve polysorbate 80 and mannitol in water for injections (Wfl); fill in ampoules.
  • Composition active substance 20 mg Lactose 120 mg
  • Dissolve mannitol in water for injections Wfl
  • Add human serum albumin Dissolve the active ingredient while heating; fill up to batch volume with Wfl; Fill into ampoules under nitrogen gas.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des antagonistes du CGRP de formule générale (I), dans laquelle A et R1 à R3 ont la définition indiquée dans la revendication 1, leurs tautomères, leurs diastéréomères, leurs énantiomères, leurs hydrates, leurs mélanges et leurs sels ainsi que les hydrates de ces sels, notamment leurs sels physiologiquement acceptables avec des acides inorganiques et organiques. L'invention concerne également des médicaments contenant ces composés, leur utilisation et leurs procédés de production.
EP05731903A 2004-04-15 2005-04-12 Antagonistes du cgrp selectionnes, leurs procedes de production et leur utilisation comme medicament Ceased EP1737864A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004018794A DE102004018794A1 (de) 2004-04-15 2004-04-15 Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
PCT/EP2005/003816 WO2005100360A1 (fr) 2004-04-15 2005-04-12 Antagonistes du cgrp selectionnes, leurs procedes de production et leur utilisation comme medicament

Publications (1)

Publication Number Publication Date
EP1737864A1 true EP1737864A1 (fr) 2007-01-03

Family

ID=34964296

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05731903A Ceased EP1737864A1 (fr) 2004-04-15 2005-04-12 Antagonistes du cgrp selectionnes, leurs procedes de production et leur utilisation comme medicament

Country Status (5)

Country Link
EP (1) EP1737864A1 (fr)
JP (1) JP2007532602A (fr)
CA (1) CA2562529A1 (fr)
DE (1) DE102004018794A1 (fr)
WO (1) WO2005100360A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
AR046787A1 (es) 2003-12-05 2005-12-21 Bristol Myers Squibb Co Agentes antimigrana heterociclicos
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
ES2433251T5 (es) 2005-11-14 2020-03-13 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
WO2007076336A1 (fr) * 2005-12-22 2007-07-05 Eli Lilly And Company Traitement de la migraine avec des anticorps anti-cgrp
WO2008021375A2 (fr) * 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulateurs de récepteurs muscariniques
WO2009034028A2 (fr) * 2007-09-07 2009-03-19 Boehringer Ingelheim International Gmbh Nouveaux composés
EP2205599B1 (fr) 2007-10-18 2012-06-06 Boehringer Ingelheim International GmbH Antagonistes du cgrp
EP2065381A1 (fr) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Antagonistes du CGRP
EP2065386A1 (fr) * 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Antagonistes du CGRP
RU2522493C2 (ru) 2008-03-04 2014-07-20 Пфайзер Лимитед Способы лечения хронической боли
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
US9855332B2 (en) 2011-05-20 2018-01-02 Alderbio Holdings Llc Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels
TWI646111B (zh) 2011-05-20 2019-01-01 艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）組成物及其用途
AU2012258980B8 (en) 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2016012188A (es) 2014-03-21 2017-04-27 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
KR20190066607A (ko) 2016-09-23 2019-06-13 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
JP2022516956A (ja) 2019-01-08 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を用いた頭痛の急性治療及び迅速治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3483893B2 (ja) * 1996-09-10 2004-01-06 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング 修飾アミノ酸、これらの化合物を含む薬物及びそれらの調製方法
CA2345357A1 (fr) * 1998-09-30 2000-04-06 Merck Sharp & Dohme Limited Piperidines de benzimidazolinyle en tant que ligands de cgrp
DE10211770A1 (de) * 2002-03-14 2003-10-02 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
AU2003237255B8 (en) * 2002-06-05 2010-01-07 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
TW200533398A (en) * 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2005100360A1 *
WERMUTH C.G.: "MOLECULAR VARIATIONS BASED ON ISOSTERIC REPLACEMENTS", PRACTICE OF MEDICINAL CHEMISTRY, 1996, pages 203 - 237, XP002190259 *

Also Published As

Publication number Publication date
WO2005100360A1 (fr) 2005-10-27
CA2562529A1 (fr) 2005-10-27
DE102004018794A1 (de) 2005-10-27
JP2007532602A (ja) 2007-11-15

Similar Documents

Publication Publication Date Title
WO2005100360A1 (fr) Antagonistes du cgrp selectionnes, leurs procedes de production et leur utilisation comme medicament
EP1737842B1 (fr) Antagonistes cgrp selectionnes, leur procede de production et leur utilisation comme medicaments
EP1732917B8 (fr) Antagonistes cgrp selectionnes, procedes de production associes et leur utilisation en tant que medicaments
EP1587795B1 (fr) Derives de n- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyle) -1-piperidine-carboxamide et composes apparentes utilises comme antagonistes de cgrp et destines au traitement des maux de tete
EP1737860A1 (fr) Antagonistes cgrp selectionnes, leur procede de production et leur utilisation comme medicaments
EP1722792A1 (fr) Antagonistes de cgrp selectionnes, procedes de fabrication et utilisation en tant que medicament
DE102004019492A1 (de) Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250082A1 (de) Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250080A1 (de) Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10211770A1 (de) Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1770091A1 (fr) Antagonistes CGRP, leur procédé de préparation ansi que leur utilisation comme médicaments
EP1931647A2 (fr) Antagonistes de cgrp selectionnes, procede pour les preparer et leur utilisation comme agents pharmaceutiques
DE102005050892A1 (de) Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE19963868A1 (de) Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1228059A1 (fr) Nouveaux cyclopropanes utilises comme antagonistes de cgrp, medicaments contenant lesdits composes et procedes permettant de les preparer
DE102005050953A1 (de) Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770087A1 (fr) Antagonistes CGRP selectionnés, leur procedé de préparation ainsi que leur utilisation comme medicaments
WO2006100026A1 (fr) 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepine-3-yl-piperidines constituant des antagonistes de cgrp
DE102004010254A1 (de) Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004028751A1 (de) Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: BA HR YU

17Q First examination report despatched

Effective date: 20070119

RAX Requested extension states of the european patent have changed

Extension state: YU

Payment date: 20061115

Extension state: HR

Payment date: 20061115

Extension state: BA

Payment date: 20061115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20080112